异基因造血干细胞移植后特发性难治性腹水:一种此前未被认识的新疾病实体
本研究在本中心观察到异基因造血干细胞移植后出现非肝硬化、非静脉闭塞病相关门静脉高压所致的漏出性难治性腹水患者,定义为特发性门静脉高压相关难治性腹水(IRA)。2004至2018年间共识别40例IRA患者,中位发生时间80天,非复发死亡累积发生率63%,发生IRA后中位生存7个月。IRA是allo-HSCT后认识不足且常致命的并发症。
要点
- IRA定义为allo-HSCT后门静脉高压(血清腹水白蛋白梯度≥1.1 g/dL或HVPG>5 mm Hg)所致腹水,且不符合经典型VOD/SOS标准、无其他门静脉高压病因。
- 40例患者中位年龄54岁,IRA中位发生时间80天,15例(38%)放置腹腔引流管。
- 19例测门静脉压力:6例(15%)中度门静脉高压(HVPG 6-9 mm Hg),13例(33%)重度(HVPG≥10 mm Hg)。
核心结论
- IRA是allo-HSCT后认识不足且常致命的并发症,非复发死亡累积发生率为63%,发生IRA后中位生存7个月(范围0.8-125.6个月)。
研究设计与样本
- 来自本中心机构数据库,2004至2018年间识别40例allo-HSCT后发生IRA的患者。
主要发现
- 患者allo-HSCT时中位年龄54岁(范围21-73岁),IRA中位发生时间80天(范围16-576天)。
- 中位腹腔穿刺次数3次(范围1-11次),15例(38%)患者放置腹腔内导管持续引流快速积聚的腹水。
- 19例测量门静脉压力:6例(15%)为中度门静脉高压(HVPG 6-9 mm Hg),13例(33%)为重度门静脉高压(HVPG≥10 mm Hg)。
- 24例接受肝活检,无一例符合经典型VOD/SOS(临床/组织学)或肝硬化(组织学)标准。
- 非复发死亡累积发生率为63%,发生IRA后中位生存7个月(范围0.8-125.6个月)。
关键数值与推荐
- IRA判定标准:继发于肝内门静脉高压的腹水(血清腹水白蛋白梯度≥1.1 g/dL或肝静脉压力梯度HVPG>5 mm Hg),但不符合经典型VOD/SOS临床标准,且无其他门静脉高压病因。
- 门静脉高压分级:中度HVPG 6-9 mm Hg,重度HVPG≥10 mm Hg。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
At our center, we observed a series of patients who developed transudative refractory ascites secondary to noncirrhotic, non-veno-occlusive disease (VOD)-related portal hypertension after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Patients were considered to have idiopathic portal hypertension-related refractory ascites (IRA) if they developed ascites secondary to intrahepatic portal hypertension (serum ascites albumin gradient ≥1.1 g/dL or hepatic venous pressure gradient [HVPG] >5 mm Hg), but did not meet the clinical criteria for classical VOD/sinusoidal obstructive syndrome (SOS) and did not have any alternate etiology of portal hypertension. From our institutional database, we identified 40 patients who developed IRA after allo-HSCT between 2004 and 2018. The patients' median age at the time of allo-HSCT was 54 years (range, 21-73 years). The median time to development of IRA after allo-HSCT was 80 days (range, 16-576 days). The median number of paracentesis was 3 (range, 1-11), and 15 (38%) patients had an intraperitoneal catheter placed for continued drainage of the rapidly accumulating ascites. Portal pressures were measured in 19 patients; 6 (15%) had moderate portal hypertension (HVPG 6-9 mm Hg), and 13 (33%) had severe portal hypertension (HVPG ≥ 10 mm Hg). Liver biopsy was performed in 24 patients. None of the patients met the criteria for classical VOD/SOS (clinical/histological) or cirrhosis (histological). The cumulative incidence of nonrelapse mortality was 63%, and the median survival duration after the development of the IRA was 7 months (range, 0.8-125.6 months). IRA is a poorly understood and often fatal complication of allo-HSCT.
引用
- Varma A, Abraham SC, Mehta RS, et al. Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity. Blood Adv. 2020. PMID: 32236526. doi:10.1182/bloodadvances.2019000638
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。